HDM2005

DRUG3 trials

Sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorsDiffuse Large B Cell Lymphoma (DLBCL)Refractory LymphomaRelapsed Hematologic Malignancy

Phase 1

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

RecruitingNCT06615193

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy

Start: 2024-08-12End: 2028-02-01Target: 111Updated: 2024-09-26

A Study of HDM2005 in Patients With Advanced Solid Tumor

RecruitingNCT07004296

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2025-05-29End: 2027-12-01Target: 72Updated: 2025-06-08

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

RecruitingNCT07124936

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Diffuse Large B Cell Lymphoma (DLBCL)

Start: 2025-07-30End: 2029-10-25Target: 97Updated: 2025-08-15

Related Papers

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Blood2025-11-03